Spirohome, an Ankara, Turkey-based digital health startup, raised a seed funding round of undisclosed amount.
Backers included ACT Venture Partners and 500 Istanbul, an early-stage VC fund within the Silicon Valley based 500 Startups network.
The company will use the proceeds to further develop the platform, grow the team and apply for both the CE mark, and the FDA regulatory process.
Led by co-founder and CEO Merthan Ozturk and Kerem Yasar, co-founder and CTO, Spirohome provides an eHealth platform solution for tracking and managing the conditions of asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF) patients as well as people who want to be aware of their lung condition.
The solution, which includes a personal smart spirometer, an integrated mobile app and a web platform for both patients and health professionals, enables patients to monitor their situation and prevent attacks while avoiding unnecessary hospital visits. Patent pending technology behind the personal spirometer uses ultrasonic flow sensing to capture lung function with medical-grade accuracy without requiring maintenance or calibration for personal use.